S&P 500   4,576.17 (+0.03%)
DOW   35,785.50 (+0.08%)
QQQ   381.04 (+0.51%)
AAPL   149.36 (+0.03%)
MSFT   319.77 (+3.12%)
FB   314.88 (-0.29%)
GOOGL   2,844.76 (+2.10%)
TSLA   1,055.31 (+3.62%)
AMZN   3,402.35 (+0.78%)
NVDA   246.09 (-0.44%)
BABA   170.97 (+0.58%)
NIO   40.99 (+1.28%)
CGC   13.22 (+0.38%)
GE   105.19 (-2.09%)
AMD   124.52 (+1.29%)
MU   67.79 (-1.67%)
T   25.30 (-0.28%)
F   15.72 (-1.38%)
ACB   7.04 (+0.14%)
DIS   170.62 (-0.83%)
PFE   43.14 (-0.96%)
BA   209.27 (-0.26%)
AMC   36.14 (+0.25%)
S&P 500   4,576.17 (+0.03%)
DOW   35,785.50 (+0.08%)
QQQ   381.04 (+0.51%)
AAPL   149.36 (+0.03%)
MSFT   319.77 (+3.12%)
FB   314.88 (-0.29%)
GOOGL   2,844.76 (+2.10%)
TSLA   1,055.31 (+3.62%)
AMZN   3,402.35 (+0.78%)
NVDA   246.09 (-0.44%)
BABA   170.97 (+0.58%)
NIO   40.99 (+1.28%)
CGC   13.22 (+0.38%)
GE   105.19 (-2.09%)
AMD   124.52 (+1.29%)
MU   67.79 (-1.67%)
T   25.30 (-0.28%)
F   15.72 (-1.38%)
ACB   7.04 (+0.14%)
DIS   170.62 (-0.83%)
PFE   43.14 (-0.96%)
BA   209.27 (-0.26%)
AMC   36.14 (+0.25%)
S&P 500   4,576.17 (+0.03%)
DOW   35,785.50 (+0.08%)
QQQ   381.04 (+0.51%)
AAPL   149.36 (+0.03%)
MSFT   319.77 (+3.12%)
FB   314.88 (-0.29%)
GOOGL   2,844.76 (+2.10%)
TSLA   1,055.31 (+3.62%)
AMZN   3,402.35 (+0.78%)
NVDA   246.09 (-0.44%)
BABA   170.97 (+0.58%)
NIO   40.99 (+1.28%)
CGC   13.22 (+0.38%)
GE   105.19 (-2.09%)
AMD   124.52 (+1.29%)
MU   67.79 (-1.67%)
T   25.30 (-0.28%)
F   15.72 (-1.38%)
ACB   7.04 (+0.14%)
DIS   170.62 (-0.83%)
PFE   43.14 (-0.96%)
BA   209.27 (-0.26%)
AMC   36.14 (+0.25%)
S&P 500   4,576.17 (+0.03%)
DOW   35,785.50 (+0.08%)
QQQ   381.04 (+0.51%)
AAPL   149.36 (+0.03%)
MSFT   319.77 (+3.12%)
FB   314.88 (-0.29%)
GOOGL   2,844.76 (+2.10%)
TSLA   1,055.31 (+3.62%)
AMZN   3,402.35 (+0.78%)
NVDA   246.09 (-0.44%)
BABA   170.97 (+0.58%)
NIO   40.99 (+1.28%)
CGC   13.22 (+0.38%)
GE   105.19 (-2.09%)
AMD   124.52 (+1.29%)
MU   67.79 (-1.67%)
T   25.30 (-0.28%)
F   15.72 (-1.38%)
ACB   7.04 (+0.14%)
DIS   170.62 (-0.83%)
PFE   43.14 (-0.96%)
BA   209.27 (-0.26%)
AMC   36.14 (+0.25%)
NASDAQ:CNCE

Concert Pharmaceuticals Stock Forecast, Price & News

$2.74
+0.05 (+1.86 %)
(As of 10/26/2021 12:00 AM ET)
Add
Compare
Today's Range
$2.64
$2.80
50-Day Range
$2.77
$3.79
52-Week Range
$2.64
$13.50
Volume97,489 shs
Average Volume290,511 shs
Market Capitalization$88.16 million
P/E RatioN/A
Dividend YieldN/A
Beta0.47
30 days | 90 days | 365 days | Advanced Chart
Receive CNCE News and Ratings via Email

Sign-up to receive the latest news and ratings for Concert Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.


Concert Pharmaceuticals logo

About Concert Pharmaceuticals

Concert Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which discovers and develops novel small molecule drugs through the use of deuterium technology. Its product candidates target a range of diseases including autoimmune disorders, inflammation, and central nervous system disorders. The company was founded by Richard H. Aldrich, Roger D. Tung and Christoph H. Westphal on April 12, 2006 and is headquartered in Lexington, MA.

Headlines

See More Headlines

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:CNCE
Employees
71
Year Founded
N/A

Sales & Book Value

Annual Sales
$7.90 million
Book Value
$4.28 per share

Profitability

Net Income
$-74.77 million
Net Margins
-174.60%

Debt

Price-To-Earnings

Miscellaneous

Market Cap
$88.16 million
Next Earnings Date
11/4/2021 (Estimated)
Optionable
Optionable

MarketRank

Overall MarketRank

2.26 out of 5 stars

Medical Sector

301st out of 1,363 stocks

Pharmaceutical Preparations Industry

137th out of 667 stocks

Analyst Opinion: 3.5Community Rank: 4.7Dividend Strength: 0.0Insider Behavior: 2.5Valuation: 0.6 5 -4 -3 -2 -1 -












Concert Pharmaceuticals (NASDAQ:CNCE) Frequently Asked Questions

Is Concert Pharmaceuticals a buy right now?

4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Concert Pharmaceuticals in the last twelve months. There are currently 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Concert Pharmaceuticals stock.
View analyst ratings for Concert Pharmaceuticals
or view top-rated stocks.

What stocks does MarketBeat like better than Concert Pharmaceuticals?

Wall Street analysts have given Concert Pharmaceuticals a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Concert Pharmaceuticals wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is Concert Pharmaceuticals' next earnings date?

Concert Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Thursday, November 4th 2021.
View our earnings forecast for Concert Pharmaceuticals
.

How were Concert Pharmaceuticals' earnings last quarter?

Concert Pharmaceuticals, Inc. (NASDAQ:CNCE) issued its quarterly earnings results on Thursday, August, 5th. The biotechnology company reported $0.16 earnings per share for the quarter, beating the Thomson Reuters' consensus estimate of ($0.72) by $0.88. The biotechnology company earned $32.02 million during the quarter. Concert Pharmaceuticals had a negative trailing twelve-month return on equity of 47.22% and a negative net margin of 174.60%.
View Concert Pharmaceuticals' earnings history
.

How has Concert Pharmaceuticals' stock been impacted by COVID-19?

Concert Pharmaceuticals' stock was trading at $8.35 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, CNCE shares have decreased by 67.2% and is now trading at $2.74.
View which stocks have been most impacted by COVID-19
.

What price target have analysts set for CNCE?

4 equities research analysts have issued 12-month price targets for Concert Pharmaceuticals' stock. Their forecasts range from $9.00 to $25.00. On average, they anticipate Concert Pharmaceuticals' stock price to reach $18.25 in the next year. This suggests a possible upside of 566.1% from the stock's current price.
View analysts' price targets for Concert Pharmaceuticals
or view top-rated stocks among Wall Street analysts.

Who are Concert Pharmaceuticals' key executives?

Concert Pharmaceuticals' management team includes the following people:
  • Roger D. Tung, President, Chief Executive Officer & Director
  • Nancy Stuart, Chief Operating Officer
  • Marc A. Becker, Chief Financial & Accounting Officer (LinkedIn Profile)
  • Julie Fields Liu, Vice President-Research & Development Management
  • Virginia Braman, Vice President-Clinical Development

What is Roger Tung's approval rating as Concert Pharmaceuticals' CEO?

1 employees have rated Concert Pharmaceuticals CEO Roger Tung on Glassdoor.com. Roger Tung has an approval rating of 100% among Concert Pharmaceuticals' employees. This puts Roger Tung in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Concert Pharmaceuticals own?

What is Concert Pharmaceuticals' stock symbol?

Concert Pharmaceuticals trades on the NASDAQ under the ticker symbol "CNCE."

Who are Concert Pharmaceuticals' major shareholders?

Concert Pharmaceuticals' stock is owned by a number of retail and institutional investors. Top institutional shareholders include Assenagon Asset Management S.A. (0.73%). Company insiders that own Concert Pharmaceuticals stock include James V Cassella, Jeffrey A Munsie, Marc A Becker, Nancy Stuart, Roger D Tung and Thomas G Auchincloss.
View institutional ownership trends for Concert Pharmaceuticals
.

Which major investors are buying Concert Pharmaceuticals stock?

CNCE stock was bought by a variety of institutional investors in the last quarter, including Assenagon Asset Management S.A..
View insider buying and selling activity for Concert Pharmaceuticals
or or view top insider-buying stocks.

How do I buy shares of Concert Pharmaceuticals?

Shares of CNCE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Concert Pharmaceuticals' stock price today?

One share of CNCE stock can currently be purchased for approximately $2.74.

How much money does Concert Pharmaceuticals make?

Concert Pharmaceuticals has a market capitalization of $88.16 million and generates $7.90 million in revenue each year. The biotechnology company earns $-74.77 million in net income (profit) each year or ($2.40) on an earnings per share basis.

How many employees does Concert Pharmaceuticals have?

Concert Pharmaceuticals employs 71 workers across the globe.

What is Concert Pharmaceuticals' official website?

The official website for Concert Pharmaceuticals is www.concertpharma.com.

Where are Concert Pharmaceuticals' headquarters?

Concert Pharmaceuticals is headquartered at 65 HAYDEN AVENUE SUITE 3000N, LEXINGTON MA, 02421.

How can I contact Concert Pharmaceuticals?

Concert Pharmaceuticals' mailing address is 65 HAYDEN AVENUE SUITE 3000N, LEXINGTON MA, 02421. The biotechnology company can be reached via phone at (781) 860-0045 or via email at [email protected].


This page was last updated on 10/27/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.